KIMBERLY DANIELS: Open Payments
NPI 1184074197 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,966 in 142 payments from 21 companies in 2025. Trend: 2023 $3,315 · 2024 $2,924 · 2025 $2,966
Food & beverage: $2,966
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $770 |
| Janssen Biotech, Inc. | 21 | $522 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $305 |
| Ardelyx, Inc. | 10 | $227 |
| Madrigal Pharmaceuticals | 11 | $226 |
| Phathom Pharmaceuticals, Inc. | 12 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $143 |
| Lilly USA, LLC | 4 | $142 |
| Sumitomo Pharma America, Inc. | 1 | $93 |
| Aimmune Therapeutics, Inc. | 4 | $63 |
Products named: TREMFYA, IBSRELA, REZDIFFRA, XIFAXAN, VRAYLAR, VOQUEZNA, MAVYRET, LINZESS.
Industry payments across AR — which companies pay providers there.
